对耶氏肺孢子菌肺炎患者进行复方磺胺甲唑治疗药物监测的重要性研究

Importance of drug monitoring for compound sulfamethoxazole therapy in patients with Pneumocystis jiroveci pneumonia

耶氏肺孢子菌肺炎(Pneumocystis jiroveci pneumonia,PJP)是人类免疫缺陷病毒(human immunodefi-ciency virus,HIV)患者较为常见和严重的机会性感染之一。随着免疫抑制剂及化疗药物等的使用,目前国内报道PJP多数为非HIV免疫抑制患者。复方磺胺甲唑(sulfamethoxazole complex,SMZco)是治疗PJP的一线药物,其药动学存在广泛的个体差异。本文通过引用1例药物监测下SMZco治疗PJP的病例,从SMZco的药代动力学、剂量相关不良反应以及最佳治疗剂量研究等方面进行系统综述,旨在表明对PJP患者进行SMZco治疗药物监测的重要性,通过药物监测以确保患者达到有效治疗浓度,减少不良反应的发生。

Pneumocystis jiroveci pneumonia(PJP)is one of the more common and serious opportunistic infections in patients with human immunodeficiency virus(HIV).With the use of immunosuppressants and chemotherapy drugs,most PJP cases reported in China are non-HIV immunosuppressed patients.Compound sulfamethoxazole(SMZco)is the first-line drug for the treatment of PJP,and there are wide individual differences in its pharmacokinetics.Through citing a PJP case treated with SMZco under drug monitoring,a systematic review was conducted from the aspects of SMZco pharmacokinetics,dose-related adverse reactions,and optimal therapeutic dose research.It aims to demonstrate the importance of drug monitoring for sulfamethoxazole therapy,which ensures the drug reaches effective therapeutic concentrations and the occurrence of its’adverse reactions was reduced.